ATE441429T1 - Ghrelin-träger-konjugate - Google Patents
Ghrelin-träger-konjugateInfo
- Publication number
- ATE441429T1 ATE441429T1 AT03765046T AT03765046T ATE441429T1 AT E441429 T1 ATE441429 T1 AT E441429T1 AT 03765046 T AT03765046 T AT 03765046T AT 03765046 T AT03765046 T AT 03765046T AT E441429 T1 ATE441429 T1 AT E441429T1
- Authority
- AT
- Austria
- Prior art keywords
- ghrelin
- provides
- ordered
- compositions
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0012—Lipids; Lipoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/18011—Details ssRNA Bacteriophages positive-sense
- C12N2795/18111—Leviviridae
- C12N2795/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Child & Adolescent Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39663802P | 2002-07-19 | 2002-07-19 | |
| PCT/EP2003/007849 WO2004009124A2 (en) | 2002-07-19 | 2003-07-18 | Ghrelin-carrier conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE441429T1 true ATE441429T1 (de) | 2009-09-15 |
Family
ID=30770928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03765046T ATE441429T1 (de) | 2002-07-19 | 2003-07-18 | Ghrelin-träger-konjugate |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20040076645A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1523372B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2006504653A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20050027168A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1665565A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE441429T1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0311800A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2489008A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60329106D1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL165003A (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA04011247A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ537001A (cg-RX-API-DMAC7.html) |
| PL (1) | PL375522A1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2325202C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004009124A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200408894B (cg-RX-API-DMAC7.html) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2407897A1 (en) * | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Molecular antigen arrays and vaccines |
| US7094409B2 (en) * | 2001-01-19 | 2006-08-22 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
| US7264810B2 (en) * | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
| US7128911B2 (en) | 2001-01-19 | 2006-10-31 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
| US7115266B2 (en) | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
| EP1513552B1 (en) * | 2002-06-20 | 2010-12-01 | Cytos Biotechnology AG | Packaged virus-like particles in combination with cpg for use as adjuvants with allergens : method of preparation and use |
| NZ537003A (en) | 2002-07-18 | 2008-03-28 | Cytos Biotechnology Ag | Hapten-carrier conjugates comprising virus like particles and uses thereof |
| CN101711865A (zh) * | 2002-07-19 | 2010-05-26 | 希托斯生物技术股份公司 | 含有淀粉样β1-6抗原阵列的疫苗组合物 |
| CA2496687A1 (en) * | 2002-09-18 | 2004-04-01 | Centre Hospitalier De L'universite De Montreal (Chum) | Ghrh analogues |
| EP1605972A2 (en) | 2003-03-26 | 2005-12-21 | Cytos Biotechnology AG | Hiv-peptide-carrier-conjugates |
| RU2006130006A (ru) * | 2004-01-20 | 2008-02-27 | Цитос Биотехнологи Аг (Ch) | Конъюгаты грелин-носитель |
| GB0411014D0 (en) * | 2004-05-18 | 2004-06-23 | Haptogen Ltd | Methods for the control treatment and management of obesity |
| KR20070059207A (ko) | 2004-10-05 | 2007-06-11 | 사이토스 바이오테크놀로지 아게 | Vlp-항원 컨쥬게이트 및 백신으로서 그의 용도 |
| WO2006045796A2 (en) * | 2004-10-25 | 2006-05-04 | Cytos Biotechnology Ag | Gastric inhibitory polypeptide (gip) antigen arrays and uses thereof |
| GB0424563D0 (en) | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
| MX2007006832A (es) * | 2004-12-13 | 2007-08-07 | Cytos Biotechnology Ag | Arreglos de antigeno interleucina 15 y usos de los mismos. |
| CN101141979B (zh) | 2005-03-18 | 2013-05-08 | 赛托斯生物技术公司 | 猫变应原融合蛋白及其用途 |
| EP1899367A4 (en) * | 2005-06-10 | 2009-06-24 | Univ Singapore | Mutant allergen(s) |
| EP1736538A1 (en) | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Process for the preparative purification of virus-like-particles (VLPs) |
| EP1931383A1 (en) | 2005-09-28 | 2008-06-18 | Cytos Biotechnology AG | Interleukin-1 conjugates and uses thereof |
| US20070184068A1 (en) | 2005-12-14 | 2007-08-09 | Cytos Biotechnology Ag | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
| US7604954B2 (en) * | 2006-02-03 | 2009-10-20 | Hill's Pet Nutrition, Inc. | Method for evaluating kidney function in a feline |
| RU2008136182A (ru) * | 2006-02-09 | 2010-03-20 | Ален ДИБИ (FR) | Система для лечения поражений в бифуркации кровеносного сосуда |
| US8992928B2 (en) * | 2006-02-11 | 2015-03-31 | Victor Raso | Isolated monoclonal antibody or antigen-binding fragment that cleaves octanoylated native ghrelin |
| EP2530086B1 (en) | 2006-06-12 | 2019-03-20 | Kuros Biosciences AG | Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages |
| CA2659264C (en) * | 2006-08-01 | 2016-01-26 | The Scripps Research Institute | Immunoconjugates of ghrelin for use in vaccines and methods for controlling adiposity |
| JP2010096677A (ja) * | 2008-10-17 | 2010-04-30 | Toray Ind Inc | 抗体/抗原結合能を有する高感度免疫学測定用ナノ粒子 |
| PL222496B1 (pl) * | 2009-04-10 | 2016-08-31 | Inst Biochemii I Biofizyki Pan | Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania oraz kompozycja farmaceutyczna zawierająca wektorową cząsteczkę wirusopodobną |
| US9724381B2 (en) | 2009-05-12 | 2017-08-08 | The Administrators Of The Tulane Educational Fund | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof |
| US8883721B2 (en) | 2009-05-12 | 2014-11-11 | Mcgill University | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof |
| JP2013509434A (ja) | 2009-10-30 | 2013-03-14 | トランザイム・ファーマ,インコーポレイテッド | 大環状グレリン受容体アンタゴニストおよびインバースアゴニストならびにその使用方法 |
| EP2582715B1 (en) * | 2010-06-16 | 2018-11-28 | The Administrators of the Tulane Educational Fund | Growth hormone secretatogue receptor antagonists and uses thereof |
| JP2015503907A (ja) | 2011-12-22 | 2015-02-05 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 真核細胞のための全長抗体提示システムおよびその使用 |
| CN104302177B (zh) | 2012-05-17 | 2019-05-28 | 延伸生物科学股份有限公司 | 用于改进的药物递送的载体 |
| CA2964463C (en) | 2014-10-22 | 2024-02-13 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
| US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
| US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
| CA3010975A1 (en) | 2015-01-15 | 2016-07-21 | University Of Copenhagen | Virus-like particle with efficient epitope display |
| ES2854726T3 (es) | 2015-10-30 | 2021-09-22 | The Univ Of Copenhagen | Partícula similar a virus con presentación eficiente de epítopos |
| CN107253984B (zh) * | 2017-05-08 | 2020-09-01 | 河南金大众生物工程有限公司 | 促生长复合多肽及其应用 |
| CN112876535B (zh) * | 2021-02-08 | 2023-06-30 | 浙江华缔药业集团医药开发有限公司 | 生物活性多肽及其应用 |
| WO2023224236A1 (ko) * | 2022-05-18 | 2023-11-23 | 한국과학기술원 | 면역 회피 효능이 강화된 박테리오파지 |
| AU2023353057A1 (en) | 2022-09-30 | 2025-05-01 | Extend Biosciences, Inc. | Long-acting parathyroid hormone |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH512848A (de) * | 1970-02-25 | 1971-09-15 | Bbc Brown Boveri & Cie | Spulenwicklung und Verfahren zu deren Herstellung |
| US4918166A (en) * | 1987-04-10 | 1990-04-17 | Oxford Gene Systems Limited | Particulate hybrid HIV antigens |
| US5057540A (en) * | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| ATE139258T1 (de) * | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| GB9213601D0 (en) * | 1992-06-26 | 1992-08-12 | Mastico Robert A | Protein based delivery system |
| US5935821A (en) * | 1995-01-17 | 1999-08-10 | Board Of Trustees Of The University Of Kentucky | Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma |
| US6291653B1 (en) * | 1997-03-24 | 2001-09-18 | Zymogenetics, Inc. | Antibodies to motilin homologs |
| US6627729B1 (en) * | 1997-03-24 | 2003-09-30 | Zymogenetics, Inc. | TML peptides |
| RU2245163C2 (ru) * | 1998-11-30 | 2005-01-27 | Сайтос Байотекнолэджи АГ | Композиция (варианты), способ получения не природной упорядоченной и содержащей повторы антигенной матрицы, способ терапевтического лечения и способ иммунизации |
| US6420521B1 (en) * | 1999-06-30 | 2002-07-16 | Zymogenetics, Inc. | Short gastrointestinal peptides |
| PT1197496E (pt) * | 1999-07-23 | 2007-08-29 | Kenji Kangawa | Novos péptidos |
| US6558695B2 (en) * | 1999-12-16 | 2003-05-06 | Dermatrends, Inc. | Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers |
| US6527165B1 (en) * | 2000-03-24 | 2003-03-04 | General Electric Company | Method of making an environmental resistant brazed assembly including a wear resistant surface portion |
| CA2407897A1 (en) * | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Molecular antigen arrays and vaccines |
| CA2411667A1 (en) * | 2000-05-30 | 2001-12-06 | Merck & Co. Inc. | Ghrelin analogs |
| EP1303538A2 (en) * | 2000-07-24 | 2003-04-23 | Ardana Bioscience Limited | Ghrelin antagonists |
| US7264810B2 (en) * | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
| CA2492826C (en) * | 2001-09-14 | 2016-12-13 | Cytos Biotechnology Ag | Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use |
| CN1558774B (zh) * | 2001-10-05 | 2012-03-14 | 赛托斯生物技术公司 | 血管紧张肽-载体偶联物及其用途 |
| DK1441764T3 (da) * | 2001-11-07 | 2009-01-26 | Cytos Biotechnology Ag | Antigen-Arrays der omfatter RANKL til behandling af knoglesygdom |
| ATE419007T1 (de) * | 2001-11-07 | 2009-01-15 | Cytos Biotechnology Ag | Antigenraster welche il-5, il-13 oder eotaxin präsentieren, zur behandlung von allergischen, eosinophilen erkrankungen |
| ES2383796T3 (es) * | 2001-12-18 | 2012-06-26 | Alizé Pharma SAS | Composiciones farmacéuticas que comprenden grelina no acilada para su utilización en el tratamiento de la resistencia a la insulina |
-
2003
- 2003-07-18 KR KR1020047018442A patent/KR20050027168A/ko not_active Ceased
- 2003-07-18 US US10/622,124 patent/US20040076645A1/en not_active Abandoned
- 2003-07-18 PL PL03375522A patent/PL375522A1/xx not_active Application Discontinuation
- 2003-07-18 JP JP2004522507A patent/JP2006504653A/ja active Pending
- 2003-07-18 CN CN038151022A patent/CN1665565A/zh active Pending
- 2003-07-18 AT AT03765046T patent/ATE441429T1/de not_active IP Right Cessation
- 2003-07-18 DE DE60329106T patent/DE60329106D1/de not_active Expired - Lifetime
- 2003-07-18 CA CA002489008A patent/CA2489008A1/en not_active Abandoned
- 2003-07-18 WO PCT/EP2003/007849 patent/WO2004009124A2/en not_active Ceased
- 2003-07-18 EP EP03765046A patent/EP1523372B1/en not_active Expired - Lifetime
- 2003-07-18 RU RU2005104565/13A patent/RU2325202C2/ru not_active IP Right Cessation
- 2003-07-18 BR BR0311800-2A patent/BR0311800A/pt not_active IP Right Cessation
- 2003-07-18 NZ NZ537001A patent/NZ537001A/en not_active IP Right Cessation
- 2003-07-18 MX MXPA04011247A patent/MXPA04011247A/es not_active Application Discontinuation
-
2004
- 2004-11-03 ZA ZA200408894A patent/ZA200408894B/en unknown
- 2004-11-03 IL IL165003A patent/IL165003A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006504653A (ja) | 2006-02-09 |
| RU2005104565A (ru) | 2005-09-10 |
| KR20050027168A (ko) | 2005-03-17 |
| NZ537001A (en) | 2007-04-27 |
| US20040076645A1 (en) | 2004-04-22 |
| WO2004009124A2 (en) | 2004-01-29 |
| IL165003A (en) | 2010-02-17 |
| CA2489008A1 (en) | 2004-01-29 |
| IL165003A0 (en) | 2005-12-18 |
| AU2003257479A1 (en) | 2004-02-09 |
| BR0311800A (pt) | 2005-03-22 |
| EP1523372A2 (en) | 2005-04-20 |
| DE60329106D1 (de) | 2009-10-15 |
| ZA200408894B (en) | 2006-08-30 |
| WO2004009124A3 (en) | 2004-04-08 |
| EP1523372B1 (en) | 2009-09-02 |
| PL375522A1 (en) | 2005-11-28 |
| RU2325202C2 (ru) | 2008-05-27 |
| CN1665565A (zh) | 2005-09-07 |
| MXPA04011247A (es) | 2005-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE441429T1 (de) | Ghrelin-träger-konjugate | |
| NO20050894L (no) | Vaksinesammensetninger inneholdende beta-l-6-antigenmatriser | |
| PL369863A1 (en) | Antigen arrays for treatment of allergic eosinophilic diseases | |
| WO2002056905A3 (en) | Molecular antigen array | |
| IL161146A0 (en) | Antigen arrays for treatment of bone disease | |
| WO2006063974A3 (en) | Il-15 antigen arrays and uses thereof | |
| PL392964A1 (pl) | Antygen reaktywny wobec surowicy hiperimmunologicznej zastosowanie tego antygenu do produkcji preparatu farmaceutycznego, fragment hiperimmunologiczny antygenu, epitopy pomocnicze antygenu, szczepionka zawierająca antygen reaktywny wobec surowicy hiperimmunologicznej, preparat zawierający przeciwciała, sposób wytwarzania tego preparatu, zastosowanie preparatu do leczenia infekcji gronkowcowych oraz sposób przesiewania | |
| IL165605A0 (en) | Molecular antigen arrays | |
| ATE370745T1 (de) | Verbesserte polysaccharid- und glykokonjugat- vakzine | |
| WO2005068639A3 (en) | Particle-induced ghrelin immune response | |
| WO2003059386A3 (en) | Prion protein carrier-conjugates | |
| WO2006027300A3 (en) | Carrier conjugates of gnrh-peptides | |
| MXPA04003901A (es) | Disposiciones de antigenos para el tratamiento de enfermedades eosinofilicas alergicas. | |
| MXPA04003900A (es) | Disposiciones de antigenos para el tratamiento de enfermedades oseas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |